EHC

Encompass Health

$133.65

+1.04%
Nov 20, 2026
Bobby Quantitative Model
Encompass Health Corporation operates the largest network of inpatient rehabilitation hospitals in the United States, delivering specialized post-acute care to patients recovering from strokes, neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations. As the clear scale leader in inpatient rehabilitation — a capital-intensive, certificate-of-need-protected niche with high barriers to entry — the company is best characterized as a defensive healthcare compounder rather than a disruptor, monetizing an aging demographic and favorable payer mix (Medicare accounts for roughly two-thirds of revenue at approximately $1.07 billion). The current investor narrative centers on accelerating organic growth and margin expansion: Q3 2026 revenue rose 8.9% year-over-year to $1.61 billion with EPS of $1.52, and the stock has re-rated sharply higher following the late-October earnings beat, with shares up roughly 23% over the past year and 33% year-to-date. Debate now hinges on whether the recent vertical move — a roughly 15% surge in the final weeks of October and early November — reflects durable earnings power from new hospital openings and volume growth or an overextended momentum trade, particularly given a modest dividend and a leveraged balance sheet.

People also watch

HCA Healthcare

HCA Healthcare

HCA

Analysis
Tenet Healthcare

Tenet Healthcare

THC

Analysis
DaVita

DaVita

DVA

Analysis
Universal Health Services

Universal Health Services

UHS

Analysis
The Ensign Group, Inc.

The Ensign Group, Inc.

ENSG

Analysis

BobbyInvestment Opinion: Should I buy EHC Today?

Rating: Buy (accumulate on weakness). EHC pairs a re-accelerating top line — Q3 2026 revenue up 8.93% year-over-year to $1.6095 billion — with genuine margin expansion (operating margin 17.89% vs. 16.49% a year earlier, EBITDA margin 23.96% vs. 22.54%) at a trailing PE of 18.89x and a PEG of 0.78, a combination that supports owning the shares even after a 32.55% YTD run. The view is anchored by unanimous analyst sentiment — all six covering analysts carry Buy or Overweight ratings with no downgrades — and a consensus EPS of $9.87 that implies a forward multiple of roughly 14.3x at $140.99, leaving room for multiple expansion if estimates drift higher.

The supporting evidence is broad: EPS grew from $1.26 in Q3 2025 to $1.52 in Q3 2026 (~21%), free cash flow TTM of $457.2 million comfortably covers the $234.5 million quarterly capex bill, ROE of 23.22% reflects efficient use of a leveraged balance sheet, and the $9.80–$10.04 consensus EPS band (a ~2.5% spread) signals unusually high conviction in the earnings path. Relative strength is exceptional — +30.08% versus SPY over six months and +13.66% over one month while SPY fell 2.26% — confirming institutional accumulation in a defensive sector. Against hospital peers trading in the mid-teens to low-20s on PE and 8–11x on EV/EBITDA, EHC's 18.89x PE and 9.46x EV/EBITDA sit mid-range, so the stock is neither a premium nor a discount name.

The thesis would be invalidated by three developments: a Medicare reimbursement cut (Medicare is roughly two-thirds of revenue at ~$1.07 billion), a stall in de novo hospital ramps that breaks the 8–9% revenue growth cadence, or margin compression from wage inflation that pushes operating margin back below 17%. This Buy would upgrade to a stronger conviction if the forward multiple stayed near 14x while Q4 confirms high-teens operating margin, and would downgrade to Hold if revenue growth decelerated below 6% or the stock broke below the $131–$135 breakout shelf on heavy volume. On balance the stock is fairly valued to modestly undervalued relative to its own 12.3x–25.2x historical PE band and its sub-1.0 PEG — the recent rally has been earnings-driven rather than multiple-driven, which is the healthier setup.

Sign up to view all

EHC 12-Month Price Forecast

The forward view is constructive but tempered by positioning: EHC's fundamentals — 8.93% revenue growth, 17.89% operating margin, 23.96% EBITDA margin, and $457.2 million of TTM free cash flow — support a base case of $145–$158 as the multiple holds near 18.89x and drifts toward the 20x area of its historical band. The stock is not expensive on a PEG of 0.78 or a forward multiple near 14.3x, and unanimous Buy/Overweight coverage with no downgrades reinforces the earnings-driven nature of the rally. The offsetting factor is that at $140.99 the stock sits at 98% of its 52-week range after a 45.6% five-month move, so the risk/reward is less favorable than it was at the June low of $97.89, and the -26.22% max drawdown shows how quickly this name can reverse. I would upgrade to high confidence if Q4 confirms operating margin at or above 18% and revenue growth above 9%, and would downgrade to neutral if the stock breaks below $131 or if Medicare reimbursement rulemaking turns adverse.

Historical Price
Current Price $133.65
Average Target $133.65
High Target $153.70
Low Target $113.60

Wall Street consensus

Six analysts cover EHC, and the sentiment is uniformly bullish: the institutional ratings log shows only Buy and Overweight actions — KeyBanc (Overweight), Truist (Buy), TD Cowen (Buy), UBS (Buy), and Barclays (Overweight) — with no Hold or Sell ratings and no downgrades in the visible history. The consensus EPS estimate is $9.87 (range $9.80–$10.04) on average revenue of $9.05 billion (range $9.00–$9.18 billion). Applying the consensus EPS to the current price of $140.99 implies a forward multiple of roughly 14.3x, and the tight clustering of estimates (a spread of only about 2.5% between the low and high EPS) signals high conviction in the earnings trajectory. The consensus leans decisively bullish, consistent with the post-Q3 upgrades and reiterations on October 29–30.

The narrow estimate range is itself a signal: analysts broadly agree on the near-term earnings path, which reduces the risk of a negative surprise but also means the stock's upside now depends on multiple expansion or upward estimate revisions rather than dispersion resolution. The high EPS estimate of $10.04 assumes continued margin expansion and successful new hospital ramps, while the low of $9.80 prices in modest reimbursement pressure or slower volume growth — a remarkably tight band that suggests limited downside dispersion in fundamentals. Notably, the provided data does not include explicit price targets, so implied upside to a consensus target cannot be calculated; based on the forward multiple of ~14.3x, however, the stock is not obviously expensive relative to its growth, and the uniform Buy/Overweight stance with no recent downgrades supports a constructive view. The main risk is that with six covering analysts and a tight estimate range, the stock may be efficiently priced, leaving less room for the kind of surprise-driven re-rating that has powered the recent rally.

Drowning in data?

Find the real signal!

Bulls vs Bears: EHC Investment Factors

The bull case currently holds the stronger evidence: revenue is re-accelerating at 8.93% year-over-year, operating margin expanded 140 basis points to 17.89%, the PEG of 0.78 supports the 18.89x trailing multiple, and all six analysts are Buy/Overweight with a tight estimate band. The bear case rests less on fundamentals than on positioning — the stock is at 98% of its 52-week range after a 45.6% five-month run, with leverage (debt-to-equity 1.11) and Medicare concentration (~two-thirds of revenue) as structural vulnerabilities. The single most important tension is whether the recent vertical move reflects durable earnings power from new hospital openings or an overextended momentum trade; if Q4 confirms continued margin expansion and volume growth, the multiple is justified, but any deceleration in the ramp would expose the stock to a sharp de-rating from all-time highs.

Bullish

  • Earnings growth outpacing share price: Trailing PE of 18.89x sits below the 19.98x reading at the end of Q3 2026 even as the stock rallied, because earnings are compounding faster than the multiple. Q3 2026 EPS of $1.52 versus $1.26 in Q3 2025 is roughly 21% growth, confirming the rally is earnings-driven rather than pure re-rating.
  • Margin expansion is real and sustained: Operating margin climbed from 16.49% in Q3 2025 to 17.89% in Q3 2026, and EBITDA margin reached 23.96% in Q3 2026 versus 22.54% a year earlier. For a capital-intensive hospital operator, a high-teens operating margin with a ~24% EBITDA margin is best-in-class and shows operating leverage on new hospital ramps.
  • Revenue re-accelerating on de novo buildout: Q3 2026 revenue of $1.6095 billion rose 8.93% year-over-year, and the sequential cadence ($1.5866B Q1, $1.5974B Q2, $1.6095B Q3) shows consistent upward progression. Consensus revenue of $9.05 billion implies continued mid-to-high single-digit expansion on a large base.
  • PEG below 1.0 with uniform Buy ratings: The PEG ratio of 0.78 suggests the 18.89x trailing multiple is well-supported by expected growth, and the forward multiple of roughly 14.3x on the $9.87 consensus EPS is modest. All six covering analysts carry Buy or Overweight ratings with no downgrades, and the EPS estimate range of $9.80–$10.04 is a tight ~2.5% spread signaling high conviction.

Bearish

  • Trading at 98% of 52-week range: At $140.99 the stock sits essentially at its 52-week high of $142.51, having traveled from $97.89 in June — a 45.6% range in roughly five months. There is no overhead resistance but also no valuation cushion, and the -26.22% max drawdown shows the stock can reverse sharply from highs.
  • Leverage and thin liquidity constrain flexibility: Debt-to-equity of 1.11, total debt to capitalization of 51.1%, and a current ratio of just 1.08 leave limited cushion. Interest expense of $32.2 million in Q3 2026 consumes roughly 11% of operating income, and the capital-intensive de novo buildout ($234.5 million capex in Q3 alone) depends on continued access to debt markets.
  • Medicare concentration is a reimbursement risk: Medicare accounts for approximately $1.0677 billion of revenue — roughly two-thirds of the total — with Managed Care at $173.3 million and Medicaid at $49.6 million. A single segment and a government-heavy payer mix mean reimbursement rate changes flow almost directly to margins with no diversification buffer.
  • Momentum-driven vertical move invites profit-taking: The stock surged roughly 15% in the final weeks of October and early November, including a jump from $122.09 on October 28 to $131.49 on October 29 after Q3 results. A failure and breakdown below the $131–$135 breakout shelf would flag exhaustion and open a retest of the $120 level.

EHC Technical Analysis

EHC is in a powerful, sustained uptrend, with the 1-year price change of +23.37% and a year-to-date gain of +32.55% confirming a durable advance rather than a bounce. At the current price of $140.99, the stock sits essentially at the top of its 52-week range, which spans from a low near $97.89 (June 2026) to the current high of $142.51 (November 10, 2026) — roughly 98% of the range. This positioning signals strong momentum but also meaningful overextension risk, as there is little overhead resistance and the stock is trading at all-time-high territory where profit-taking pressure tends to build. The maximum drawdown of -26.22% over the period shows the stock is capable of sharp reversals, so chasing at the highs carries asymmetric risk.

Short-term momentum is decisively positive and accelerating: the 1-month change of +11.40% and 3-month change of +14.08% both outpace the 1-year gain, indicating the trend is steepening rather than fading. The 6-month change of +32.21% versus the 1-year +23.37% confirms that most of the annual return was generated in the last two quarters, with a notable inflection around the August 6 earnings gap (from $110.90 to $124.82 in a single session) and a second leg up after the late-October Q3 report (from $122.09 on October 28 to $131.49 on October 29). Relative strength is exceptional across every window — +13.66% versus SPY over 1 month, +16.91% over 3 months, and +30.08% over 6 months — while SPY itself is down 2.26% over the past month, underscoring EHC's status as a market leader. The absence of volume data limits confirmation, but the price action alone suggests institutional accumulation.

Key technical levels are well defined: immediate support sits at the $131–$135 zone (the late-October breakout shelf), with secondary support at the 52-week low area near $97.89 and the psychological $120 level that contained the stock through August and September. Resistance is effectively the current high of $142.51; a clean breakout above that level on strong volume would signal continuation of the momentum regime and likely invite momentum-fund inflows, while a failure and breakdown below $131 would flag a potential double-top or exhaustion gap and open the door to a retest of $120. Volatility context matters for sizing: the -26.22% max drawdown demonstrates that this is not a low-beta defensive name in practice, and with a current ratio of just 1.08 and debt-to-equity of 1.11, the equity carries operating leverage that can amplify moves in both directions. Position sizing should account for the fact that the stock has traveled from $97.89 to $142.51 — a 45.6% range — within roughly five months.

Beta

—

—

Max Drawdown

-26.2%

Largest decline past year

52-Week Range

—

Price range past year

Annual Return

+18.5%

Cumulative gain past year

PeriodEHC ReturnS&P 500
1m+10.9%-9.7%
3m+11.1%-9.9%
6m+27.3%-7.5%
1y+18.5%+4.7%
ytd+25.6%+1.2%

Bobby - Your AI Investment Partner

Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions

EHC Fundamental Analysis

Revenue is growing steadily and, importantly, re-accelerating: Q3 2026 revenue of $1.6095 billion rose 8.93% year-over-year versus $1.4775 billion in Q3 2025, and the sequential cadence ($1.5866B in Q1, $1.5974B in Q2, $1.6095B in Q3) shows consistent upward progression. The payer mix is dominated by Medicare at approximately $1.0677 billion, with Managed Care at $173.3 million, Medicaid at $49.6 million, Workers' Compensation at $8.2 million, and Patients at $8.0 million — a government-heavy mix that provides revenue stability but exposes the company to reimbursement rate risk. The growth trend supports the investment case: new hospital openings and same-store volume gains are compounding on a large base, and the consensus revenue estimate of $9.05 billion implies continued mid-to-high single-digit expansion. With a single operating segment, there is no diversification buffer, so execution on de novo hospital development is the key swing factor.

Profitability is robust and improving. Q3 2026 net income was $149.9 million on a 9.31% net margin, with operating income of $288.0 million (17.89% operating margin) and EBITDA of $385.7 million (23.96% EBITDA margin). The multi-quarter trend shows margin expansion: net margin was 8.56% in Q3 2025 and 9.46% in Q4 2025, rising to 12.26% in Q1 2026 before normalizing to 9.63% in Q2 and 9.31% in Q3 — the Q1 spike reflects seasonality and a lower tax rate, but the underlying direction is upward, with operating margin climbing from 16.49% in Q3 2025 to 17.89% in Q3 2026. Gross margin reported at 21.62% in Q3 2026 is not comparable to the 43–44% figures in prior quarters due to a reclassification of cost of revenue (Q2 2026 showed 44.51%), so the operating margin is the cleaner profitability gauge. For a capital-intensive hospital operator, a high-teens operating margin and ~24% EBITDA margin are solid and consistent with best-in-class post-acute operators.

Balance sheet and cash flow are adequate but leverage is a watch item. Debt-to-equity stands at 1.11, total debt to capitalization at 51.1%, and the current ratio at 1.08 — thin liquidity that is typical of hospital operators but leaves limited cushion. Free cash flow TTM is $457.2 million, though quarterly FCF is lumpy ($127.5M in Q3 2026, $62.3M in Q2, $150.7M in Q1) because capital expenditure is heavy at $234.5 million in Q3 alone, reflecting the de novo hospital buildout. Operating cash flow of $362.0 million in Q3 covered capex comfortably, and the company returned capital via $57.9 million of buybacks and $18.7 million of dividends. ROE of 23.22% is strong, aided by leverage, and interest coverage of roughly 8.9x provides reasonable headroom, but the capital intensity means EHC depends on continued access to debt markets to fund growth — a refinancing risk if rates rise.

Quarterly Revenue

$1.6B

2026-09

Revenue YoY Growth

+8.9%

YoY Comparison

Gross Margin

21.6%

Latest Quarter

Free Cash Flow

$457199999.0B

Last 12 Months

Revenue & Net Income Trends (2 Years)

Revenue Breakdown

Managed Care
Medicaid
Medicare
Patients
Workers' Compensation

Open an Account, get $2 TSLA now!

Valuation Analysis: Is EHC Overvalued?

Because net income is solidly positive ($149.9 million in Q3 2026 alone), the PE ratio is the appropriate primary metric. EHC trades at a trailing PE of 18.89x, which is modest for a healthcare compounder, and the PEG ratio of 0.78 suggests the multiple is well-supported by expected growth. The forward PE of 0.78 in the provided data appears to be a data artifact (it matches the PEG ratio exactly and is inconsistent with the $9.87 consensus EPS, which would imply a forward PE near 14.3x at $140.99); using the consensus EPS of $9.87, the forward multiple of roughly 14.3x versus 18.9x trailing implies the market expects meaningful earnings growth — approximately 32% — over the next twelve months, a gap that reflects confidence in margin expansion and new hospital ramps.

Against the Medical - Care Facilities industry, EHC's 18.89x trailing PE and 9.46x EV/EBITDA sit in a reasonable range — hospital operators typically trade in the mid-teens to low-20s on PE and 8–11x on EV/EBITDA, so EHC is neither a clear premium nor a discount name. The 1.80x PS ratio and 4.37x price-to-book are moderate for a capital-intensive operator, while the 9.07x price-to-cash-flow reflects strong cash generation. The 0.67% dividend yield and 12.56% payout ratio are token, signaling that capital is being reinvested into growth rather than returned — appropriate for a company building hospitals. On balance, the valuation looks fair-to-attractive relative to the growth profile, with the PEG below 1.0 being the most compelling data point.

Historically, EHC's PE has ranged from roughly 12.3x (Q1 2026) to 25.2x (Q3 2025), with the current 18.89x sitting near the middle of that band and below the 19.98x reading at the end of Q3 2026 — meaning the stock has gotten cheaper on earnings even as the price has risen, because earnings growth has outpaced the share-price advance. The PS ratio of 1.80x in the provided data is inconsistent with the historical series (which shows 6–8x), likely a market-cap or share-count discrepancy, so the PE and EV/EBITDA are the more reliable anchors. The current multiple is not stretched versus its own history, which supports the view that the recent rally is earnings-driven rather than multiple-driven — a healthier setup than a pure re-rating.

PE

18.9x

Latest Quarter

vs. Historical

Mid-Range

5-Year PE Range 12x~25x

vs. Industry Avg

18.9x

Industry PE ~18.9x*

EV/EBITDA

9.5x

Enterprise Value Multiple

Investment Risk Disclosure

Financial and operational risks center on leverage and capital intensity. Debt-to-equity of 1.11 and total debt to capitalization of 51.1% mean the balance sheet carries meaningful fixed obligations, with $32.2 million of quarterly interest expense consuming roughly 11% of Q3 2026 operating income. The current ratio of just 1.08 leaves thin liquidity, and free cash flow is lumpy ($127.5M in Q3, $62.3M in Q2, $150.7M in Q1) because capex is heavy at $234.5 million in Q3 alone to fund de novo hospitals. Revenue concentration compounds this: Medicare is roughly two-thirds of the $1.61 billion quarterly top line, and with a single operating segment there is no diversification buffer if reimbursement rates tighten or volume growth slows.

Market and competitive risks are primarily valuation and positioning. At $140.99 the stock trades at 98% of its 52-week range after a 45.6% move from the June low of $97.89, and the -26.22% max drawdown demonstrates that this defensive-sector name behaves with high beta in practice. The 18.89x trailing PE and 9.46x EV/EBITDA are fair rather than cheap versus hospital peers in the mid-teens to low-20s PE and 8–11x EV/EBITDA range, so there is little multiple cushion if growth disappoints. Certificate-of-need protection limits new entrants, but large health systems and post-acute competitors continue to expand capacity, and any Medicare reimbursement rulemaking would hit the entire sector simultaneously. Recent coverage already hints at caution — one Zacks note cited mixed operating metrics and a Hold rating despite the Q3 beat.

The worst-case scenario is a reimbursement cut or volume deceleration arriving just as the stock sits at all-time highs. A disappointing Q4 — slower de novo ramps, softer Medicare rates, or margin compression from wage inflation — would likely trigger profit-taking from momentum holders and a retest of the $131–$135 breakout shelf, then the $120 level that contained the stock through August and September. A fuller de-rating toward the 52-week low of $97.89 would represent roughly -31% from the current $140.99, and a reversion to the Q1 2026 PE low of 12.3x on the $9.87 consensus EPS would imply about $121, or roughly -14%. Investors should size positions for a realistic -15% to -30% drawdown in an adverse scenario.

FAQ

Ranked by severity: first, reimbursement concentration — Medicare accounts for approximately $1.0677 billion, or roughly two-thirds of quarterly revenue, so a single adverse rate update in the inpatient rehabilitation facility rulemaking would hit margins directly with no diversification buffer. Second, balance-sheet leverage — debt-to-equity of 1.11, total debt to capitalization of 51.1%, and a current ratio of just 1.08 leave thin liquidity, while $32.2 million of quarterly interest expense consumes roughly 11% of operating income and the $234.5 million quarterly capex bill depends on continued debt-market access. Third, valuation and positioning risk — at 98% of the 52-week range after a 45.6% move from the June low, the stock has no valuation cushion, and the -26.22% max drawdown shows how sharply it can reverse; a break below $131 could open a retest of $120. Fourth, operational execution — slower de novo hospital ramps or nurse and therapist wage inflation pushing operating margin back below 17% would break the 8–9% growth cadence that underpins the entire thesis.

The 12-month forecast is weighted toward the base case at 55% probability, targeting $145–$158 (roughly 3–12% above $140.99), assuming revenue growth of 8–9%, operating margin holding in the 17.5–18.0% range, stable Medicare rates, and a multiple near the current 18.89x drifting toward 20x. The bull case carries 25% probability with a $160–$172 target, driven by Q4 EPS at or above the $10.04 high estimate, operating margin at or above 18%, and a re-rating toward the 20x-plus end of the historical band. The bear case carries 20% probability with a $98–$121 target, triggered by a Medicare cut, margin compression below 17%, or a breakdown below the $131–$135 shelf that retests $120 and potentially the $97.89 low. The most likely outcome is the base case, and its key assumption is that the de novo hospital buildout keeps revenue compounding at 8–9% while reimbursement stays stable.

EHC looks fairly valued to modestly undervalued rather than stretched. The trailing PE of 18.89x sits near the middle of its historical 12.3x–25.2x band and below the 19.98x reading at the end of Q3 2026, meaning the stock has gotten cheaper on earnings even as the price rose. The PEG of 0.78 and forward multiple of roughly 14.3x on the $9.87 consensus EPS imply the market expects about 32% earnings growth over the next twelve months, a gap that reflects confidence in margin expansion and new hospital ramps. Against hospital peers trading in the mid-teens to low-20s on PE and 8–11x on EV/EBITDA, EHC's 18.89x PE and 9.46x EV/EBITDA are mid-range — neither a premium nor a discount. The 1.80x PS and 4.37x price-to-book are moderate for a capital-intensive operator, and the 9.07x price-to-cash-flow reflects strong cash generation; the market is paying a fair price for a defensive compounder, not a premium for a growth story.

From a risk/reward standpoint, EHC offers a favorable but no longer exceptional entry: at $140.99 it trades at 18.89x trailing earnings and roughly 14.3x the $9.87 consensus EPS, with a PEG of 0.78 and unanimous Buy/Overweight coverage from all six analysts. The upside case is a grind to the $145–$158 base range (3–12%) or $160–$172 if margins push above 18%, while the downside case is a retest of $120 (-15%) or the $97.89 52-week low (-31%) if Q4 disappoints. The biggest risk is that the stock sits at 98% of its 52-week range after a 45.6% five-month move, so the margin of safety is thinner than it was at the June low. It is a good buy for patient investors seeking defensive healthcare exposure with earnings-driven momentum, particularly on pullbacks toward the $131–$135 shelf, but less attractive for anyone chasing at all-time highs without a stop discipline.

EHC is primarily a long-term holding, though its recent momentum makes it tradeable for disciplined short-term investors. The long-term case rests on an aging demographic, certificate-of-need-protected inpatient rehabilitation capacity, a 23.22% ROE, $457.2 million of TTM free cash flow, and a de novo buildout that compounds revenue at 8–9% — a profile suited to a multi-year hold of at least 12–24 months to let new hospitals ramp and margins expand. The short-term case is weaker on risk/reward: the stock is at 98% of its 52-week range after a 45.6% five-month move, and the -26.22% max drawdown shows it can reverse sharply, so momentum traders should use the $131–$135 shelf as a stop. The token 0.67% dividend yield and 12.56% payout ratio mean there is no income cushion to support a hold through drawdowns. A concrete suggestion: a minimum 12-month holding period for core positions, with new capital added on pullbacks toward $131–$135 rather than at current highs.